Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $25.42 USD
Change Today -0.52 / -2.00%
Volume 297.6K
AEGR On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark J. Fitzpatrick

Chief Financial Officer and Principal Accounting Officer, Aegerion Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 4 different industries.

As of Fiscal Year 2013


Mr. Mark J. Fitzpatrick has been the Chief Financial Officer of Aegerion Pharmaceuticals Inc since May 9, 2011 and has been its Principal Accounting Officer since February 29, 2012. Mr. Fitzpatrick has over 18 years experience in the financial management of biotechnology and high technology companies. Mr. Fitzpatrick served as a Vice President and Chief Financial Officer of Proteon Therapeutics, Inc. since 2007 and also served as its Assistant Secretary. Mr. Fitzpatrick ...

Read Full Background

Corporate Headquarters*

One Main Street
Cambridge, Massachusetts 02142

United States

Phone: 617-500-7867
Fax: 617-945-7968

Board Members Memberships*

There is no Board Members Memberships data available.


Unknown/Other Education
Carroll School of Management of Boston College
Carroll School of Management of Boston College

Other Affiliations*

Annual Compensation*

Total Annual Compensation$350,000

Stock Options*

All Other Compensation$7,650
Exercised Options20,350
Exercised Options Value$1,491,916
Exercisable Options88,733
Exercisable Options Value$4,633,259
Unexercisable Options138,417
Unexercisable Options Value$6,890,429
Total Value of Options$17,885,154
Total Number of Options342,500

Total Compensation*

Total Annual Cash Compensation$560,650
Total Short Term Compensation$350,000
Other Long Term Compensation$7,650
Total Calculated Compensation$1,888,489
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $25.42 USD -0.52


Stanley T. Crooke M.D., Ph.D.Founder, Executive Chairman, Chief Executive Officer, President, Chairman of Science/Medical Committee and Member of Agenda Committee
Isis Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at